PD-1 inhibition has achieved a remarkable response in EBV-positive lymphoma and EBV-associated gastric cancer, in which it is believed to reverse EBV or cancer-mediated immunosuppression by restoring immunity and releasing T cells [15–19]. Here, PDCD1 is linked to gastric cancer.